证券代码：688193 证券简称：仁度生物 公告编号：2023-028 上海仁度生物科技股份有限公司监事会 关于公司 2023 年限制性股票激励计划 激励对象名单的审核意见及公示情况说明 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海仁度生物科技股份有限公司（以下简称"公司"）于 2023 年 7 月 31 日 召开的第一届董事会第十六次会议、第一届监事会第十三次会议审议通过了《关 于<上海仁度生物科技股份有限公司 2023 年限制性股票激励计划（草案）>及其 摘要的议案》等议案。根据《上市公司股权激励管理办法》（以下简称"《管理 办法》"）的相关规定，公司对《上海仁度生物科技股份有限公司 2023 年限制 性股票激励计划（草案）》（以下简称"本激励计划"）中确定的激励对象名单 在公司内部进行了公示。公司监事会根据《管理办法》相关规定，在征询公示意 见后对拟激励对象名单进行核查，相关公示情况及核查结果如下： 一、公示情况及核查方式 公司于 2023 年 8 月 1 日、2023 年 8 月 8 日在上海证券交易所网站 ...

上海仁度生物科技股份有限公司 2023 年第一次临时股东大会会议资料 证券代码：688193 证券简称：仁度生物 上海仁度生物科技股份有限公司 2023 年第一次临时股东大会会议资料 2023 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"证券法"）《上市公司股东大会规则》以及《上 海仁度生物科技股份有限公司章程》（以下简称"《公司章程》"）《上海仁度生物 科技股份有限公司股东大会议事规则》等相关规定，上海仁度生物科技股份有限 公司（以下简称"公司"）特制定 2023 年第一次临时股东大会会议须知： 一、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，出席 会议的股东及股东代理人须在会议召开前 15 分钟到会议现场办理签到手续，并 请按规定出示证券账户卡、身份证明文件或企业营业执照/注册证书复印件（加 盖公章）、授权委托书等，经验证后领取会议资料，方可出席会议。会议开始后， 会议登记应当终止，由会议主持人宣布现场出席会议的股东和代理人人数及所 ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2023, representing a 20% increase compared to the same period last year [1]. - The company's operating revenue for the first half of 2023 was ¥80,029,969.73, a decrease of 52.83% compared to ¥169,661,995.80 in the same period last year [21]. - The net profit attributable to shareholders for the first half of 2023 was -¥10,192,633.27, representing a decline of 146.50% from ¥21,921,636.24 in the previous year [21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥14,555,699.40, a decrease of 185.06% compared to ¥17,112,955.88 in the same period last year [21]. - The net cash flow from operating activities was -¥13,947,402.37, worsening from -¥5,296,678.95 in the previous year [21]. - The basic earnings per share for the first half of 2023 were -¥0.25, a decline of 139.68% from ¥0.63 in the same period last year [22]. - The diluted earnings per share for the first half of 2023 were -¥0.25, a decrease of 140.32% compared to ¥0.62 in the previous year [22]. - The company's total comprehensive income for the first half of 2023 was a loss of CNY 8,677,861.92, compared to a profit of CNY 22,320,634.80 in the same period of 2022 [196]. Research and Development - Research and development expenses increased by 30% to 150 million RMB, focusing on enhancing the SAT technology platform [1]. - Research and development investment increased by 26.76% year-on-year, accounting for 23.24% of operating revenue [24]. - The company reported a total R&D expenditure of ¥18,600,816.46 for the current period, representing a 26.76% increase compared to ¥14,674,416.73 in the same period last year [48]. - The company has developed core technologies in molecular diagnostics, including RNA real-time fluorescence isothermal amplification technology and multiple RNA amplification detection technology, all sourced from independent research and development [42]. - The company has seen a significant increase in R&D personnel and compensation, contributing to the rise in R&D expenditures [49]. Market Expansion and Product Development - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024 [1]. - New product launches include a novel RNA detection kit, expected to contribute an additional 100 million RMB in revenue by Q4 2023 [1]. - The company has developed a complete molecular diagnostic industry chain, including core raw materials, reagents, instruments, and third-party testing services [28]. - The company aims to expand its market presence by providing systematic solutions to medical institutions and independent laboratories [32]. - The company has launched innovative diagnostic products, including the world's first HBV RNA detection kit, which offers significant advantages over traditional HBV DNA testing [62]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance [1]. - The company faces risks related to the loss of core technical personnel, which could adversely affect ongoing and future projects [72]. - There is a risk of intensified market competition, particularly in the RNA detection market, as many new entrants are emerging [74]. - The company is exposed to potential changes in tax incentives and government subsidies, which could negatively impact its financial performance [77]. - The global macroeconomic environment may affect healthcare spending, potentially slowing demand for in vitro diagnostic products [79]. Shareholder and Governance Commitments - The controlling shareholder commits not to engage in any competing business during their control period, ensuring no direct or indirect competition with the company [107]. - The company commits to a profit distribution policy prioritizing cash dividends, with a minimum cash dividend ratio of 80% during mature stages without major capital expenditures [126]. - The company will ensure that any share reduction does not violate commitments made during the IPO process [113]. - The company has committed to ensuring the authenticity, accuracy, and completeness of its IPO prospectus and related documents, taking legal responsibility for any false statements or omissions that may cause investor losses [131]. - The company will publicly disclose any failure to fulfill commitments and apologize to shareholders if necessary [130]. Environmental and Social Responsibility - The company invested 4.10 million yuan in environmental protection during the reporting period [99]. - The company has established a wastewater treatment system that complies with Shanghai's local standards for wastewater discharge [100]. - Solid waste is managed by a qualified third-party hazardous waste disposal company, ensuring proper handling of waste materials [101]. - The company has implemented noise reduction measures to meet the industrial noise emission standards [101]. - The company has integrated energy-saving and emission reduction concepts into its daily operations [103].

Financial Performance - The net profit attributable to shareholders for 2022 was RMB 23,331,394.53, representing a profit margin of approximately 21.43% of the total profit distributed to shareholders[6]. - The company plans to distribute a cash dividend of RMB 1.25 per 10 shares, totaling RMB 5,000,000.00, based on a total share capital of 40 million shares as of December 31, 2022[6]. - As of December 31, 2022, the company's distributable profits amounted to RMB 100,659,989.86[6]. - The company has not yet achieved profitability since its listing[4]. - The company's operating revenue for 2022 was approximately ¥303.85 million, representing a year-over-year increase of 3.95% compared to ¥292.31 million in 2021[23]. - Net profit attributable to shareholders decreased by 63.89% to approximately ¥23.33 million from ¥64.62 million in 2021[23]. - The basic earnings per share fell by 71.16% to ¥0.62, while diluted earnings per share decreased by 71.36% to ¥0.61[24]. - The net cash flow from operating activities dropped by 107.51%, resulting in a negative cash flow of approximately ¥4.09 million[25]. - The company's total assets increased by 187.56% to approximately ¥1.09 billion, up from ¥378.61 million in 2021[23]. - The company reported a total revenue of 13,000.00 million RMB, with a net profit of 3,155.65 million RMB, reflecting a significant increase in performance compared to the previous year[81]. Research and Development - Research and development expenses grew by 29.91%, accounting for 11.25% of operating revenue, up from 9% in the previous year[24]. - The company applied for 50 patents, including 28 invention patents and 22 utility model patents, enhancing its competitive barrier[36]. - The company has developed a fully automated nucleic acid detection system that can process samples without manual intervention, achieving a "sample in, result out" workflow, significantly improving efficiency[45]. - The company has established a comprehensive core technology system for molecular diagnostic reagents, enhancing its competitive edge in the market[73]. - The total R&D investment for the year was approximately ¥34.19 million, representing a 29.91% increase from the previous year, with R&D expenses accounting for 11.25% of total revenue[78]. Market and Product Development - The company is actively involved in the development of new diagnostic technologies and products, aiming to expand its market presence[12]. - The company’s strategic focus includes enhancing its product offerings and exploring potential mergers and acquisitions to drive growth[12]. - The company has developed a range of molecular diagnostic reagent products, including the first SAT-based nucleic acid test kits for Chlamydia trachomatis and Neisseria gonorrhoeae in China, addressing unmet clinical needs[41]. - The company launched the world's first HBV RNA detection product for hepatitis B, which is now used in several provinces including Shandong and Fujian[64]. - The company aims to become a leading developer and supplier of molecular diagnostic products, focusing on unmet clinical needs in the RNA diagnostics field[138]. Corporate Governance - The company has not yet achieved profitability since its listing[4]. - The company does not have any special arrangements for corporate governance[8]. - The company has established a governance framework that includes a board of directors, supervisory board, and various specialized committees to ensure effective oversight and decision-making[142]. - There were no significant differences between the company's governance practices and the regulations set forth by the China Securities Regulatory Commission[142]. - The company has maintained a presence in academic institutions, with board members holding positions at universities, which may facilitate research collaborations and innovation[155]. Operational Risks and Challenges - The company faces challenges due to a shift in revenue structure, leading to a decrease in gross profit contribution[26]. - The company is exposed to competition from both domestic and international players, which may impact its market position if it cannot maintain technological leadership[96]. - The company must navigate regulatory challenges, as new products require extensive approval processes that can take 3-5 years[94]. - The company is at risk of new product development failures due to high costs, long cycles, and potential misalignment with market needs[93]. - The company faces risks related to significant revenue declines if conventional business growth cannot offset declines in pandemic-related business[92]. Environmental and Social Responsibility - The company invested 4.8 million yuan in environmental protection during the reporting period[191]. - The company is not listed as a key pollutant discharge unit and has no instances of exceeding emission standards[192]. - The company has established an environmental protection management system and has clear responsibilities for waste disposal and emissions[195]. - The company donated 81.23 million yuan to local Red Cross societies to support pandemic prevention efforts[197]. Future Outlook - The company anticipates continued growth in the in vitro diagnostic market, driven by an aging population and rising healthcare demands[134]. - The molecular diagnostics market is expected to lead the in vitro diagnostics industry, with applications in various medical fields[134]. - The molecular diagnostics market in China is expected to grow rapidly, driven by increasing clinical demand and technological advancements, with a focus on RNA diagnostics[135]. - The Chinese government is promoting a health-centered approach, emphasizing early screening and prevention in infectious disease management, which will benefit RNA diagnostics[137].

Financial Performance - The company's operating revenue for Q1 2023 was ¥38,766,500.34, representing a decrease of 58.44% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥6,392,335.66, reflecting a decline of 138.03% year-over-year[5]. - Basic and diluted earnings per share were both -¥0.16, down 128.57% from the same period last year[6]. - Total operating revenue for Q1 2023 was ¥38,766,500.34, a decrease of 58.5% compared to ¥93,280,166.18 in Q1 2022[20]. - Net profit for Q1 2023 was a loss of ¥6,392,335.66, compared to a profit of ¥16,806,634.77 in Q1 2022, representing a significant decline[20]. - The company experienced a comprehensive loss of ¥6,909,010.22 in Q1 2023, compared to a comprehensive income of ¥16,784,019.05 in Q1 2022[21]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥6,213,384.20, a decrease of 204.23% compared to the previous year[6]. - In Q1 2023, the net cash flow from operating activities was -$6,213,384.20, a significant decline from $5,961,279.66 in Q1 2022[24]. - Total cash inflow from operating activities was $67,228,828.74, down from $74,655,779.92 in the same quarter last year, representing a decrease of approximately 10.5%[24]. - Cash outflow from operating activities increased to $73,442,212.94 from $68,694,500.26, marking an increase of about 6.5% year-over-year[24]. - The total cash and cash equivalents at the end of Q1 2023 were $273,236,061.29, down from $875,430,465.48 at the end of Q1 2022, reflecting a decrease of approximately 68.9%[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,066,374,019.29, a decrease of 2.05% from the end of the previous year[6]. - Total liabilities decreased to ¥110,652,691.07 in Q1 2023 from ¥127,337,004.79 in Q1 2022, indicating a reduction of 13.1%[17]. - The company's total assets as of Q1 2023 were ¥1,066,374,019.29, a decrease from ¥1,088,721,710.38 in the previous year[17]. Research and Development - Research and development expenses totaled ¥8,518,167.13, an increase of 17.21% year-over-year, accounting for 21.97% of operating revenue, up 12.35 percentage points[6]. - Research and development expenses increased to ¥8,518,167.13 in Q1 2023, up from ¥7,267,729.68 in Q1 2022, reflecting a focus on innovation[20]. - The company is accelerating multiple ongoing projects to enhance future growth potential, which contributed to the increase in R&D expenses[9]. Shareholder Information - The top shareholder,居金良, holds 19.65% of the shares with a total of 7,858,357 shares[12]. - MING LI INVESTMENTS LIMITED is the second-largest shareholder with 15.44%, holding 6,176,624 shares[12]. - The company has a total of 10 major shareholders, with the top 10 holding significant stakes in the company[13]. Operational Insights - The decline in revenue was attributed to a significant drop in pandemic-related testing products, despite a recovery in routine testing reagent business[9]. - The report indicates no significant changes in the company's operational strategies or new product developments during the quarter[14]. - The company has not provided specific guidance for future performance or market expansion plans in this report[14].

证券代码：688193 证券简称：仁度生物 公告编号：2023-014 届时公司的董事长居金良先生、董事兼总经理于明辉女士、董事兼副总经理 曹若华女士、独立董事徐宗宇先生、董事会秘书兼财务总监蔡廷江先生将通过网 络在线交流形式与投资者就公司治理、发展战略、经营状况、现金分红方案、可 持续发展等投资者关注的问题进行沟通；如有特殊情况，上述参会人员可能进行 调整。 欢迎广大投资者积极参与。 特此公告。 上海仁度生物科技股份有限公司董事会 2023 年 4 月 26 日 为进一步加强与广大投资者的沟通交流，上海仁度生物科技股份有限公司 （以下简称"公司"）将参加"2023 年上海辖区上市公司年报集体业绩说明会" 活动。现将有关事项公告如下： 本次业绩说明会活动将采取网络的方式举行，投资者可以登录"上证路演中 心"网站（http://roadshow.sseinfo.com）或关注微信公众号"上证路演中心" 参与活动，活动时间为 2023 年 5 月 10 日（周三）15:00 至 17:00。 上海仁度生物科技股份有限公司 关于参加 2023 年上海辖区上市公司年报集体 业绩说明会的公告 本公司董事会及全体董事保证 ...

证券简称：仁度生物 证券代码：688193 上海仁度生物科技股份有限公司 投资者关系活动记录表 （2022 年 4 月） | --- | --- | --- | |------------------------|----------------------------------|-----------------------------------------------------| | | | | | | ☑ | 特定对象调研 □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | □电话会议 | | | □其他 | （请文字说明其他活动内容） | | | | 诺德基金、深圳泽正私募证券投资基金管理有限公司、 | | 参与单位名称 | 理有限公司 | 深圳市泰聚私募证券基金管理有限公司、中庚基金管 | | | | | | 会议时间 2022 | 年 4 月 | | | 参会方式 通讯方式 | | | | 上市公司接待人员姓名 | 董事长： 居金良 | | | | 董事兼总经理： 杨孝华 | | | | 董事兼副总 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥70,433,694.06, a decrease of 15.57% compared to the same period last year[5] - The net profit attributable to shareholders was ¥1,833,062.99, down 89.92% year-on-year, while the net profit after deducting non-recurring gains and losses was a loss of ¥4,661,307.85, a decrease of 127.80%[5] - The company reported a basic earnings per share of ¥0.08, down 86.89% compared to the same period last year[6] - Total operating revenue for the first three quarters of 2022 reached ¥240,095,689.86, an increase of 7.3% compared to ¥223,558,205.60 in the same period of 2021[20] - Net profit for the first three quarters of 2022 was ¥23,754,699.23, a decrease of 53.7% compared to ¥51,221,003.23 in the same period of 2021[21] - The total comprehensive income attributable to the parent company for Q3 2022 was CNY 24,596,836, a decrease from CNY 51,183,075 in Q3 2021, representing a decline of approximately 52%[22] - Basic earnings per share for Q3 2022 were CNY 0.71, down from CNY 1.71 in Q3 2021, reflecting a decrease of about 58%[22] Expenses and Costs - Research and development expenses totaled ¥11,411,247.87, an increase of 55.49% year-on-year, accounting for 16.20% of operating revenue, up 7.40 percentage points[6] - Total operating costs for the first three quarters of 2022 were ¥220,908,652.51, up 31.9% from ¥167,482,998.67 in the previous year[20] - Research and development expenses for the first three quarters of 2022 amounted to ¥26,085,664.60, an increase of 44.3% from ¥18,077,334.81 in the previous year[20] - The company’s financial expenses showed a net income of -¥2,969,612.75, compared to -¥1,288,575.20 in the previous year, indicating a worsening financial position[20] Assets and Liabilities - Total assets reached ¥1,086,541,740.11, representing a year-on-year increase of 186.98%[6] - Total liabilities as of the end of Q3 2022 were ¥120,260,478.88, compared to ¥90,860,601.43 at the end of Q3 2021, reflecting a year-over-year increase of 32.4%[19] - The company’s total current assets were reported at ¥975,116,140.92, compared to ¥282,537,896.95 in the previous year, showing a growth of approximately 245%[17] - The company’s total current liabilities increased to ¥91,879,525.49, compared to ¥66,306,799.11 in the previous year, marking a rise of 38.7%[19] - Total equity attributable to shareholders reached ¥966,281,261.23, significantly up from ¥287,747,428.24 in the same period last year[19] Cash Flow - Cash flow from operating activities was negative at -¥15,431,886.63, a decrease of 169.25%[6] - Net cash flow from operating activities for the first three quarters of 2022 was negative CNY 15,431,886.63, compared to positive CNY 22,284,045.82 in the same period of 2021[23] - Cash inflow from investment activities in the first three quarters of 2022 was CNY 744,498,273.44, significantly higher than CNY 23,340,056.29 in the same period of 2021[23] - The net cash flow from investment activities for the first three quarters of 2022 was negative CNY 110,972,110.31, compared to negative CNY 14,398,788.51 in the same period of 2021[23] - Cash inflow from financing activities for the first three quarters of 2022 was CNY 675,692,000, compared to CNY 3,000,000 in the same period of 2021[23] - The net increase in cash and cash equivalents for the first three quarters of 2022 was CNY 526,725,061.46, compared to CNY 5,174,896.68 in the same period of 2021[23] - The ending balance of cash and cash equivalents as of the end of Q3 2022 was CNY 723,992,494.80, up from CNY 176,775,609.59 at the end of Q3 2021[23] - The company reported a significant increase in cash received from investment recoveries, totaling CNY 737,110,730.59 in the first three quarters of 2022, compared to CNY 22,000,000 in the same period of 2021[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,481[12] - The report indicates that there are no significant changes in the shareholder structure or related party transactions that could impact the company's operations[15] Other Information - The company has not disclosed any new product launches or technological advancements during this quarter[15] - There were no significant mergers or acquisitions reported in the third quarter of 2022[15] - The company has not provided specific future guidance or market expansion strategies in the current report[15] - The company has not executed any mergers or acquisitions during the reporting period, with no net profit reported from merged entities[22]

Financial Performance - The company reported a total revenue of 688 million CNY for the first half of 2022, reflecting a year-on-year increase of 15%[1]. - The gross profit margin for the period was 45%, indicating a stable performance compared to the previous year[1]. - The company's operating revenue for the first half of 2022 was ¥169,661,995.80, representing a 21.07% increase compared to ¥140,134,514.79 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2022 was ¥21,921,636.24, a decrease of 33.64% from ¥33,035,932.10 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,112,955.88, down 46.66% from ¥32,085,110.10 year-on-year[21]. - The net cash flow from operating activities was -¥5,296,678.95, a decline of 140.50% compared to ¥13,077,820.92 in the same period last year[21]. - The net profit attributable to shareholders decreased by 33.64%, primarily due to a decline in sales revenue and gross margin of COVID-19 testing products[22]. - Operating cash flow decreased by 140.5% year-on-year, attributed to longer collection periods from some clients despite increased testing service revenue[22]. - The company achieved operating revenue of 169.66 million yuan, a year-on-year increase of 21.07%[71]. - The net profit attributable to shareholders decreased by 33.64% to CNY 21.92 million[85]. Market Expansion and Product Development - The company has set a revenue guidance of 1.5 billion CNY for the full year 2022, representing a growth target of 10%[1]. - New product launches included two innovative diagnostic kits, which are expected to contribute an additional 200 million CNY in revenue by the end of the year[1]. - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by Q4 2022[1]. - The company is focusing on expanding its product offerings in RNA molecular diagnostics, which is increasingly recognized for its clinical advantages over DNA diagnostics[41]. - The company has developed RNA detection products for various infections, including chlamydia, gonorrhea, and tuberculosis, leveraging the higher RNA copy numbers for more sensitive and accurate results[42]. - The company has successfully launched the AutoSAT, the first domestic high-throughput fully automated RNA nucleic acid detection analysis system, which streamlines the entire process from extraction to result analysis[47]. - The company has developed a new HBV RNA testing kit, addressing a market of approximately 70 million hepatitis B patients in China[73]. - The company is developing a fully automated nucleic acid detection system, which is expected to enhance testing capabilities across various sample types[56]. Research and Development - Research and development expenses increased by 25% to 100 million CNY, focusing on enhancing RNA detection technologies[1]. - R&D investment as a percentage of operating income increased by 0.99 percentage points to 8.65%[22]. - R&D expenses increased by 36.66% year-over-year, totaling approximately ¥14.67 million compared to ¥10.74 million in the same period last year[51]. - The company is focusing on product development, accelerating clinical research and registration for over ten projects, including hepatitis C, HIV, and HPV RNA[52]. - The company has developed the AutoSAT, the first fully automated, high-throughput RNA detection system in China, capable of meeting emergency testing needs[63]. Risk Management and Compliance - The report emphasizes the importance of risk management strategies in addressing potential operational risks[1]. - The company faced risks related to the loss of core technical personnel, which could impact ongoing projects and competitive advantage[78]. - There is a risk of intensified market competition, particularly from established multinational companies in the molecular diagnostics sector[80]. - The company noted that local outbreaks of COVID-19 could lead to fluctuations in sales and operational performance[82]. - The company emphasized the importance of maintaining effective quality control across its production processes to safeguard its reputation and operational integrity[83]. Shareholder Commitments and Corporate Governance - The controlling shareholder, Ju Jinliang, has committed to avoiding any business activities that may compete directly or indirectly with the company's main business during his tenure as the actual controller[113]. - The company will not engage in any related party transactions that could harm the interests of the company and its shareholders[115]. - The company commits to a profit distribution policy prioritizing cash dividends, with a minimum cash dividend ratio of 80% during mature stages without significant capital expenditures[134]. - The company will ensure that any commitments made regarding shareholding and reduction are adhered to, or it will publicly explain the reasons for non-compliance[133]. - The company will take necessary measures according to relevant laws and regulations if it fails to fulfill commitments, including stopping cash dividends and salary payments[163]. Financial Position and Assets - Total assets at the end of the reporting period were ¥1,087,586,153.33, reflecting a 187.26% increase from ¥378,608,029.67 at the end of the previous year[21]. - Cash and cash equivalents reached ¥846,196,037.31, an increase of 327.50% compared to ¥197,942,433.34 in the previous period[92]. - Accounts receivable increased to ¥98,828,668.19, up 78.65% from ¥55,319,058.41, attributed to longer customer payment terms[92]. - Inventory rose to ¥26,478,402.14, a 36.59% increase from ¥19,385,461.30, mainly due to increased raw material and product reserves[92]. - Total liabilities increased to ¥51,719,367.98, a rise of 77.84% from ¥29,081,567.08, mainly due to increased payable expenses[92].

Financial Performance - The company's revenue for Q1 2022 was ¥93,280,166.18, representing a year-over-year increase of 7.43%[3] - The net profit attributable to shareholders decreased by 13.54% to ¥16,806,634.77[3] - The basic earnings per share for the period was ¥0.56, down 13.54% from the previous year[3] - The weighted average return on equity decreased by 2.95 percentage points to 5.66%[3] - Net profit for Q1 2022 was ¥16,806,634.77, down from ¥19,437,639.40 in Q1 2021, a decrease of about 13.4%[18] - The total comprehensive income for Q1 2022 was ¥16,784,019.05, compared to ¥19,480,470.18 in Q1 2021, a decrease of about 13.9%[18] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 192.07% to ¥5,961,279.66[3] - The company's cash and cash equivalents as of March 31, 2022, amounted to RMB 874,755,465.48, significantly up from RMB 197,942,433.34 at the end of 2021, representing a growth of 341.5%[13] - Cash flow from operating activities generated a net amount of ¥5,961,279.66 in Q1 2022, up from ¥2,041,065.05 in Q1 2021, indicating a significant improvement[21] - Cash and cash equivalents at the end of Q1 2022 totaled ¥875,430,465.48, compared to ¥167,029,781.05 at the end of Q1 2021, reflecting a substantial increase[22] - Investment activities resulted in a net cash outflow of ¥3,466,731.24 in Q1 2022, an improvement from a net outflow of ¥5,099,308.39 in Q1 2021[22] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,083,745,413.96, an increase of 186.24% compared to the end of the previous year[4] - The total liabilities as of March 31, 2022, were RMB 124,399,111.98, up from RMB 90,860,601.43, indicating a growth of 37%[15] - Total current assets reached RMB 982,345,585.28, compared to RMB 282,537,896.95 at the end of 2021, marking an increase of 248.5%[13] - The total equity attributable to shareholders increased by 233.40% to ¥959,346,301.98[4] - The total equity attributable to shareholders increased to RMB 959,346,301.98 from RMB 287,747,428.24, a rise of 233.5%[15] Research and Development - Research and development expenses amounted to ¥7,267,729.68, accounting for 7.79% of revenue, an increase of 0.14 percentage points[4] - Research and development expenses rose to ¥7,267,729.68 in Q1 2022, compared to ¥6,643,350.37 in Q1 2021, an increase of approximately 9.4%[17] - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[16] Strategic Outlook - The company reported non-recurring gains of ¥705,846.34 after tax[7] - The company reported a net profit margin improvement, with net profit for Q1 2022 expected to reflect positive growth trends[16] - The company has plans for strategic partnerships and potential acquisitions to bolster its market position and drive future growth[16] - The management provided optimistic guidance for the upcoming quarters, anticipating continued revenue growth and improved operational efficiency[16] Operating Costs - Total operating costs increased to ¥73,195,654.95 in Q1 2022 from ¥62,782,489.99 in Q1 2021, representing an increase of approximately 17.5%[17] - Total operating revenue for Q1 2022 was RMB 93,280,166.18, an increase of 7.8% compared to RMB 86,825,799.85 in Q1 2021[16] - Total revenue from sales of goods and services received cash of ¥74,344,188.17 in Q1 2022, down from ¥85,652,644.15 in Q1 2021, a decline of about 13.5%[21] Shareholder Information - The total number of common shareholders at the end of the reporting period was 9,049[9] - The company recorded investment income of ¥735,301.12 in Q1 2022, significantly higher than ¥114,622.64 in Q1 2021, marking an increase of approximately 540.5%[17]